Clindamycin treatment of chronic pharyngeal carriage of group A streptococci. 1991

R R Tanz, and J R Poncher, and K E Corydon, and K Kabat, and R Yogev, and S T Shulman
Division of General Academic and Emergency Pediatrics, Children's Memorial Hospital, Chicago, IL 60614.

We previously demonstrated that chronic pharyngeal carriage of group A beta-hemolytic streptococci (GABHS) can be terminated by intramuscular administration of benzathine penicillin plus 4 days of orally administered rifampin. Because an effective oral regimen would be desirable, we compared clindamycin with P + R for treating GABHS carriage. Healthy, symptom-free GABHS carriers were randomly assigned to receive orally administered clindamycin (20 mg/kg per day) three times a day for 10 days or intramuscularly administered benzathine penicillin with oral doses of rifampin (20 mg/kg per day) twice a day for 4 days. Compliance was documented by antibiotic activity in urine. Throat cultures for GABHS were obtained every 3 weeks for up to 9 weeks after treatment. Patients who had positive throat cultures for their original GABHS T type 3 weeks after randomization were crossed over to the other treatment. Treatment success was defined as eradication of the original GABHS T type, with all follow-up cultures negative. Clindamycin eradicated carriage in 24 (92%) of 26 patients; penicillin plus rifampin was effective in 12 (55%) of 22 patients (p less than 0.025). Including patients crossed over 3 weeks after enrollment, clindamycin was effective in 28 (85%) of 33 treatment courses compared with 12 of 22 courses of penicillin plus rifampin (p less than 0.05). We conclude that 10 days of oral clindamycin therapy was significantly more effective than benzathine penicillin plus 4 days of orally administered rifampin for treatment of symptom-free GABHS carriers.

UI MeSH Term Description Entries
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D010401 Penicillin G Benzathine Semisynthetic antibiotic prepared by combining the sodium salt of penicillin G with N,N'-dibenzylethylenediamine. Benzathine Penicillin,Bencelin,Benzathine Benzylpenicillin,Benzathine Benzylpénicilline Panpharma,Benzetacil,Bicillin,Bicillin L-A,Brevicilina,Cepacilina,Debecillin,Extencilline,Pendepon,Penduran,Pendysin,Penicillin G Benzathine Anhydrous,Penidural,Peniroger Retard,Permapen,Provipen Benzatina,Tardocillin,Benzathine, Penicillin G,Benzylpenicillin, Benzathine,Bicillin L A,Bicillin LA,Penicillin, Benzathine
D010612 Pharyngitis Inflammation of the throat (PHARYNX). Sore Throat,Pharyngitides,Sore Throats,Throat, Sore
D002353 Carrier State The condition of harboring an infective organism without manifesting symptoms of infection. The organism must be readily transmissible to another susceptible host. Asymptomatic Carrier State,Asymptomatic Infection Carrier,Inapparent Infection Carrier,Presymptomatic Carrier State,Presymptomatic Infection Carrier,Super-spreader Carrier,Superspreader Carrier,Asymptomatic Carrier States,Asymptomatic Infection Carriers,Carrier State, Asymptomatic,Carrier State, Presymptomatic,Carrier States,Carrier, Super-spreader,Carrier, Superspreader,Carriers, Super-spreader,Carriers, Superspreader,Inapparent Infection Carriers,Infection Carrier, Asymptomatic,Infection Carrier, Inapparent,Infection Carrier, Presymptomatic,Presymptomatic Carrier States,Presymptomatic Infection Carriers,Super spreader Carrier,Super-spreader Carriers,Superspreader Carriers
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D002981 Clindamycin An antibacterial agent that is a semisynthetic analog of LINCOMYCIN. 7-Chloro-7-deoxylincomycin,Chlolincocin,Chlorlincocin,Cleocin,Clindamycin Hydrochloride,Clindamycin Monohydrochloride,Clindamycin Monohydrochloride, Monohydrate,Dalacin C,7 Chloro 7 deoxylincomycin,Hydrochloride, Clindamycin,Monohydrate Clindamycin Monohydrochloride,Monohydrochloride, Clindamycin,Monohydrochloride, Monohydrate Clindamycin

Related Publications

R R Tanz, and J R Poncher, and K E Corydon, and K Kabat, and R Yogev, and S T Shulman
February 2007, The Pediatric infectious disease journal,
R R Tanz, and J R Poncher, and K E Corydon, and K Kabat, and R Yogev, and S T Shulman
June 1985, The Journal of pediatrics,
R R Tanz, and J R Poncher, and K E Corydon, and K Kabat, and R Yogev, and S T Shulman
August 2006, The Indian journal of medical research,
R R Tanz, and J R Poncher, and K E Corydon, and K Kabat, and R Yogev, and S T Shulman
August 1977, Journal of clinical microbiology,
R R Tanz, and J R Poncher, and K E Corydon, and K Kabat, and R Yogev, and S T Shulman
November 1983, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
R R Tanz, and J R Poncher, and K E Corydon, and K Kabat, and R Yogev, and S T Shulman
May 1970, British medical journal,
R R Tanz, and J R Poncher, and K E Corydon, and K Kabat, and R Yogev, and S T Shulman
September 2000, Lancet (London, England),
R R Tanz, and J R Poncher, and K E Corydon, and K Kabat, and R Yogev, and S T Shulman
August 1983, The Journal of infectious diseases,
R R Tanz, and J R Poncher, and K E Corydon, and K Kabat, and R Yogev, and S T Shulman
April 1986, European journal of clinical microbiology,
R R Tanz, and J R Poncher, and K E Corydon, and K Kabat, and R Yogev, and S T Shulman
October 1980, Journal of clinical pathology,
Copied contents to your clipboard!